Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Tue Apr 01 16:51:55 GMT 2025
by
admin
on
Tue Apr 01 16:51:55 GMT 2025
|
| Source Materials Class | ORGANISM |
| Source Materials Type | VIRUS |
| Organism Family | Retroviridae |
| Organism Genus | Lentivirus |
| Organism Species | human immunodeficiency virus 1 |
| Author | NONE |
| Part | whole |
| Record UNII |
859A956UY8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
859A956UY8
Created by
admin on Tue Apr 01 16:51:55 GMT 2025 , Edited by admin on Tue Apr 01 16:51:55 GMT 2025
|
PRIMARY | |||
|
100000175418
Created by
admin on Tue Apr 01 16:51:55 GMT 2025 , Edited by admin on Tue Apr 01 16:51:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR->TARGET ORGANISM |
Other
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
HIV maturation inhibitor: Exhibited robust antiviral activity against a panel of HIV-1 clinical isolates, with a mean EC50 of 9?nM
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
The observation of gastrointestinal intolerability and the emergence of resistant virus led to the cessation of development activities in favor of compounds with improved antiviral profiles.
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Upregulates innate immunity
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
IN-VITRO
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
infected with HIV-luc/VSV-G (1 ng p24Gag).
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
IC50 values (50% inhibitory
concentration) ranged from 10-100 nM against laboratory and clinical isolates of HIV-1.
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
An Fc-aglycosylated, non–T-cell–depleting and CD4-specific humanized IgG1 derived from the parent murine B4, which binds to discontinuous, conformational epitopes on the HIV-receptor complex, including CD4 domain 1, and competitively blocks HIV entry
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Tipranavir (TPV) is a non-peptidic HIV-1 protease inhibitor that inhibits the virus-specific processing of the viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Upregulates innate immunity
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
DOES NOT ACTIVATE CCR5
IC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
|
INHIBITOR->TARGET ORGANISM |
INHIBITS BINDING
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
EC50
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
NNRTI
|
||
|
|
INHIBITOR->TARGET ORGANISM |
Inhibits cytopathic effect
EC50
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
The in vitro results showed that the EC50 of BILR 355 was 0.26 ng/ml (0.59 nM) against wild-type HIV-1 and ranged from 1.5 to 13 ng/ml (3.4 –29 nM) against clinically common single and double NNRTI mutations .
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|